NASDAQ: RAPP - Rapport Therapeutics, Inc.

Lønnsomhet i seks måneder: -50.93%
Utbytte: 0.00%
Sektor: Healthcare

Kampanjeplan Rapport Therapeutics, Inc.

Avansert tidsplan Enkel graf
Financial Markets by TradingView

Om selskapet Rapport Therapeutics, Inc.

Rapport Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder.

flere detaljer
The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.
Legg til i sammenligningslisten
Legg til overvåkningsliste
Legg til portefølje
Legg til prisvarsel

IPO date 2024-06-07
Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.rapportrx.com
Цена ао 9.7
Prisendring per dag: +3.61% (9.7)
Prisendring per uke: +3.4% (9.72)
Prisendring per måned: -8.97% (11.04)
Prisendring over 3 måneder: -47.19% (19.03)
Prisendring over seks måneder: -50.93% (20.48)
Prisendring siden begynnelsen av året: -43.35% (17.74)
Alle parametere

Undervurdering

Navn Betydning Karakter
P/S 0 0
P/BV 12.05 1
P/E 0 0
EV/EBITDA -43.63 0
Total: 0.625

Effektivitet

Navn Betydning Karakter
ROA, % -33.3 0
ROE, % -35.09 0
Total: 0

Utbytte

Navn Betydning Karakter
Div yield, % 0 0
DSI 0 0
Total: 0

Plikt

Navn Betydning Karakter
Debt/EBITDA -0.0178 10
Total: 9.8

Vekstimpuls

Navn Betydning Karakter
Lønnsomhet Revenue, % 0 0
Lønnsomhet Ebitda, % 702.31 10
Lønnsomhet EPS, % 29.66 4
Total: 6.8
Flere detaljer

ETFDele, %Lønnsomhet for året, %Utbytte, %
iShares Neuroscience and Healthcare ETF 0.71137 19.72 0.03
iShares Micro-Cap ETF 0.04983 17.09 1.54048
iShares Russell 2000 Growth ETF 0.00794 38.04 0.6026
0.2624.950.72



Veileder Stillingstittel Betaling Fødselsår
Dr. Steven M. Paul M.D. Founder & Independent Chairman 1951 (74 år)
Mr. Abraham N. Ceesay M.B.A. CEO, President, Treasurer & Director 1978 (47 år)
Dr. Troy A. Ignelzi Chief Financial Officer 1968 (57 år)
Ms. Cheryl Gault Chief Operating Officer 1979 (46 år)
Mr. David Bredt M.D., Ph.D. Founder & Chief Scientific Officer 1965 (60 år)
Ms. Karina Chmielewski Chief Information Officer & Head of Operations
Ms. Julie DiCarlo Head of Communications & Investor Relations
Ms. Kathleen A. Wilkinson Chief People Officer 1972 (53 år)
Dr. Bradley S. Galer M.D. Chief Medical Officer 1962 (63 år)
Mr. Swamy Yeleswaram Ph.D. Chief Development Officer 1963 (62 år)

Adresse: United States, Boston, 1325 Boylston Street - åpne i Google maps, åpne Yandex-kart
Nettsted: https://www.rapportrx.com